Enveric Biosciences Inc (NASDAQ: ENVB) is a clinical-stage biopharmaceutical company developing psychedelic-inspired drug candidates targeting neurological and psychiatric conditions. The company generates no product revenue, funding operations through equity issuances, including common stock offerings, at-the-market agreements, and warrant exercises, as disclosed in its 10-K filed March 27, 2026. Enveric's auditors issued a going-concern opinion dated March 27, 2026, citing recurring losses, cash used in operations, and the need to raise additional funds to sustain operations through December 31, 2025. The company advances candidates through preclinical development toward IND application filings and human clinical trials, relying on contract research organizations and third-party partners to conduct studies. No product revenue, commercial partnerships with disclosed economics, or named competitors are identified in the filing excerpts.

Revenue model

No product revenue as of the annual period ended December 31, 2025. Capital is raised through equity offerings, at-the-market stock sales, and warrant exercises. The company is pre-commercial and dependent on external financing to fund operations.

Products and services

Psychedelic-inspired drug candidates in preclinical and early clinical development. The company files IND applications for human clinical trials and conducts preclinical testing covering toxicity, safety, chemistry manufacturing and controls, and clinical protocols. Specific named product candidates are not identified in the filing excerpts.

Customers and end markets

No commercial customers as of December 31, 2025. Target end markets involve neurological and psychiatric indications addressed by psychedelic-inspired therapeutics, pending regulatory approval.

Value-chain role

Drug developer relying on contract research organizations and third-party partners for clinical trial execution, preclinical testing, and IND application support. The company does not manufacture or commercialize products as of the filing date.

Geographic exposure

Incorporated and operating in the United States, with cross-border shipment of controlled substances noted as a clinical trial risk factor. Specific geographic revenue breakdown is not disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-27

Industry: Pharmaceutical Preparations Peers: AmeriCann, Inc. /entities/nasc CNS Pharmaceuticals Inc Kiora Pharmaceuticals Inc GREEN HYGIENICS HOLDINGS INC. Johnson & Johnson Palisade Bio Inc One World Products Inc Sonoma Pharmaceuticals Inc